课题基金 / 基金详情

Priming and fusion activation of the SARS coronavirus spike glycoprotein

Priming and fusion activation of the SARS coronavirus spike glycoprotein
SARS冠状病毒刺突糖蛋白的引发和融合激活
批准号:
7879331
负责人:
Gary R Whittaker
金额:
$19.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-25 至 2012-05-31

项目摘要

项目成果

Gary R Whittaker的其他基金

相似基金

相关文献

中文摘要
翻译
简介(申请人提供):严重急性呼吸系统综合症(SARS)是一种新近出现的由冠状病毒(SARS-CoV)引起的病毒性疾病。与其他病毒系统的情况相比,关于SARS-CoV进入宿主细胞的过程,特别是膜融合事件,仍有许多悬而未决的问题。虽然SARS-CoV自最初暴发以来没有再次出现,但仍然存在进一步爆发SARS-CoV或其他动物冠状病毒的威胁。对病毒进入的详细了解对于我们应对未来暴发的能力至关重要。我们提出了两个特定的目标:1)确定SARS-CoV S2结构域中蛋白水解性切割位点在控制膜融合中的作用。我们的初步结果表明,位于SARS冠状病毒S蛋白S2区的一个新的蛋白水解性切割位点793-KPTKR-797有助于控制病毒的融合。该区域碱性残基的突变导致胰酶介导的融合丧失,在该位置引入Furin识别位点允许在没有ACE2(SARS冠状病毒受体)的情况下融合,这表明在宿主范围内发挥重要作用。我们还表明,R797的切割也通过肺表达的丝氨酸蛋白酶TMPRSS2和HAT启动膜融合。我们提出了一项全面的S2裂解位点(S2‘)的诱变和生化研究,目的是了解不同的酶对SARS-CoV S蛋白的选择性裂解如何调节病毒入侵过程中S的启动和融合激活。2)研究中性粒细胞弹性蛋白酶在S2结构域内裂解SARS冠状病毒中的作用。我们还知道,SARS冠状病毒的进入可以被弹性蛋白酶激活,这是一种促进感染的机制,在SARS冠状病毒感染者的肺部出现明显的炎症反应的情况下,这一机制尤其重要。我们的初步结果表明,中性粒细胞弹性蛋白酶也在S2‘裂解位点附近裂解,位于残基T795。我们建议对S2‘端的弹性酶裂解位点进行全面的研究,目的是了解弹性酶对SARS-CoV S蛋白的裂解如何影响病毒的入侵和融合。这个项目的重点是SARS-CoV,因为它具有高度优先的地位;然而,我们的工作很可能直接适用于其他病毒系统。总体而言,我们的研究将揭示SARS-CoV融合激活和宿主范围的关键特征。值得注意的是,S2中裂解位点的存在在整个冠状病毒科中非常保守,很可能是普遍的特征;融合反应由不同的蛋白酶启动,具体取决于个别病毒和环境。这些研究将为SARS-CoV的发病机制提供一个模型,以及了解冠状病毒如何克服物种特异性并进入新的宿主。公共卫生意义:由于2003年春季严重急性呼吸综合征(SARS)的暴发,冠状病毒作为传染病的病原体最近受到了极大的关注。虽然SARS冠状病毒自最初爆发以来没有再出现,但SARS冠状病毒或其他新型冠状病毒仍有进一步爆发的威胁。SARS冠状病毒识别宿主细胞并与宿主细胞进行膜融合的能力是其宿主范围的主要因素。我们的研究旨在阐明SARS冠状病毒融合和进入的分子细节,这将为SARS冠状病毒的发病机制和新的抗病毒药物的开发提供一个模型,并帮助我们了解冠状病毒如何克服物种特异性并进入新的宿主。
英文摘要
DESCRIPTION (provided by applicant): Severe Acute Respiratory Syndrome (SARS) is a recently emerged viral disease caused by a coronavirus (SARS-CoV). In contrast to the situation with other viral systems, there remain many unanswered questions regarding the process of SARS-CoV entry into host cells, especially with regard to membrane fusion events. While SARS-CoV has not undergone re-emergence since the initial outbreak, there remains a continued threat of further zoonotic outbreaks of SARS-CoV, or other animal coronaviruses. A detailed understanding of virus entry will be essential in our ability to respond to future outbreaks. We propose two specific aims: 1) To determine the role of a proteolytic cleavage site in the SARS-CoV S2 domain controlling membrane fusion. Our Preliminary Results indicate that a novel proteolytic cleavage site 793-KPTKR-797 within the S2 domain of the SARS coronavirus (SARS-CoV) S protein is instrumental in controlling viral fusion. Mutation of basic residues in this region leads to a loss of trypsin-mediated fusion and the introduction of a furin recognition site in this position allows fusion in the absence of ACE2 (the SARS-CoV receptor) suggesting an important role in host range. We have also shown that cleavage at R797 also primes membrane fusion via the lung-expressed serine proteases TMPRSS2 and HAT. We propose a comprehensive mutagenic and biochemical study of the S2 cleavage site (S2'), with the goal of understanding how selective cleavage of the SARS-CoV S protein by different proteases regulate S priming and fusion activation during virus entry. 2) To characterize the role of neutrophil elastase on SARS-CoV activation via cleavage within the S2 domain. It is also known that SARS-CoV entry can be activated by elastase, a mechanism of infection enhancement that is especially important in the context of the pronounced inflammatory response seen in the lungs of SARS-CoV-infected individuals. Our Preliminary Results indicate that neutrophil elastase also cleaves in the vicinity of the S2' cleavage site, at residue T795. We propose a comprehensive study of the elastase cleavage site at S2', with the goal of understanding how cleavage of the SARS-CoV S protein by elastase impacts virus entry and fusion. This project has a focus on the SARS-CoV because of its high priority status; however our work is likely to be directly applicable to other virus systems. Overall our studies will reveal critical features of SARS-CoV fusion activation and host range. Notably the presence of a cleavage site within S2 are very highly conserved across the Coronaviridae, and are likely to be universal features; with the fusion reaction primed by different proteases depending on the individual virus and circumstances. These studies will provide a model for both pathogenesis of SARS-CoV, as well as an understanding how coronaviruses might overcome species-specificity and emerge into new hosts. PUBLIC HEALTH RELEVANCE: Coronaviruses have recently received much attention as agents of infectious disease, due to the outbreak of severe acute respiratory syndrome (SARS) in the spring of 2003. While the SARS-coronavirus has not undergone re-emergence since the initial outbreak, there remains a continued threat of further outbreaks of SARS-CoV, or of other novel coronaviruses. The ability of the SARS-coronavirus to recognize and undergo membrane fusion with host cells is a major factor in its host range. Our studies are designed to elucidate the molecular details of SARS-coronavirus fusion and entry, which will serve as a model for both pathogenesis of SARS-CoV and the development of new antiviral drugs, as well as to help us understand how coronaviruses might overcome species-specificity and emerge into new hosts.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Broad-based spike protein stalk-based vaccine platform for SARS-CoV-2 and other coronaviruses
  • 批准号:
    10363311
  • 项目类别:
  • 资助金额:
    $19.63万
  • 财政年份:
    2021
  • 负责人:
    Gary R Whittaker
  • 依托单位:
Broad-based spike protein stalk-based vaccine platform for SARS-CoV-2 and other coronaviruses
  • 批准号:
    10493412
  • 项目类别:
  • 资助金额:
    $23.55万
  • 财政年份:
    2021
  • 负责人:
    Gary R Whittaker
  • 依托单位:
Development of novel protease inhibitors for influenza and paramyxoviruses
  • 批准号:
    9197959
  • 项目类别:
  • 资助金额:
    $23.49万
  • 财政年份:
    2016
  • 负责人:
    Gary R Whittaker
  • 依托单位:
Development of novel protease inhibitors for influenza and paramyxoviruses
  • 批准号:
    9035762
  • 项目类别:
  • 资助金额:
    $22.19万
  • 财政年份:
    2016
  • 负责人:
    Gary R Whittaker
  • 依托单位:
海外基金